SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cypress Bioscience Inc – ‘10-K’ for 12/31/03 – EX-10.27

On:  Monday, 3/29/04, at 6:01am ET   ·   For:  12/31/03   ·   Accession #:  1047469-4-9648   ·   File #:  0-12943

Previous ‘10-K’:  ‘10-K/A’ on 7/17/03 for 12/31/02   ·   Next:  ‘10-K’ on 3/16/05 for 12/31/04   ·   Latest:  ‘10-K’ on 3/31/10 for 12/31/09

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/29/04  Cypress Bioscience Inc            10-K       12/31/03   16:1.4M                                   Merrill Corp/New/FA

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    594K 
 2: EX-10.22    Material Contract                                   HTML     52K 
 3: EX-10.23    Material Contract                                   HTML    212K 
 4: EX-10.24    Material Contract                                   HTML     50K 
 5: EX-10.25    Material Contract                                   HTML    150K 
 6: EX-10.26    Material Contract                                   HTML    212K 
 7: EX-10.27    Material Contract                                   HTML     18K 
 8: EX-10.28    Material Contract                                   HTML     76K 
 9: EX-10.29    Material Contract                                   HTML     37K 
10: EX-10.30    Material Contract                                   HTML     37K 
11: EX-10.31    Material Contract                                   HTML     38K 
12: EX-21.1     Subsidiaries of the Registrant                      HTML      8K 
13: EX-23.1     Consent of Experts or Counsel                       HTML     11K 
14: EX-31.1     Certification per Sarbanes-Oxley Act (Section 302)  HTML     14K 
15: EX-31.2     Certification per Sarbanes-Oxley Act (Section 302)  HTML     14K 
16: EX-32.1     Certification per Sarbanes-Oxley Act (Section 906)  HTML     11K 


EX-10.27   —   Material Contract
Exhibit Table of Contents

Page (sequential) | (alphabetic) Top
 
11st Page   -   Filing Submission
"Exhibit 10.27
"Side Letter Agreement
"QuickLinks

This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]




QuickLinks -- Click here to rapidly navigate through this document


Exhibit 10.27

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4)
and 240.24B-2


Side Letter Agreement

Pierre Fabre Medicament S.A.
45 Place Abel-Gance
92654 Boulogne Cedex
France

Attention: Chief Executive Officer

Ladies and Gentlemen:

        Each of Cypress and Forest wish to confirm to each other and to Pierre Fabre, and Pierre Fabre agrees with each of Cypress and Forest, the following understanding of certain aspects of our agreement as set forth in the Letter Agreement with respect to the development and marketing of Licensed Product in Canada (unless otherwise defined herein, capitalized terms shall have the meaning set forth in the Letter Agreement):


IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement.

FOREST LABORATORIES IRELAND LIMITED   CYPRESS BIOSCIENCE, INC.

By:

 

/s/  
RAYMOND STAFFORD      

 

By:

 

/s/  
JAY KRANZLER      
Name:   Raymond Stafford
  Name:   Dr. Jay Kranzler
Title:   Chief Executive Officer
  Title:   Chief Executive Officer

PIERRE FABRE MÉDICAMENT

 

 

 

 

By:

 

/s/  
JEAN PIERRE COUZINIER      

 

 

 

 
Name:   Jean Pierre Couzinier
       
Title:   Chief Operating Officer
       

2




QuickLinks

Side Letter Agreement

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/29/043,  4,  424B5,  8-K
1/9/044,  8-K
For Period End:12/31/03
 List all Filings 
Top
Filing Submission 0001047469-04-009648   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 1:08:07.1am ET